emerging approaches to combination therapies in amd & dme
TRANSCRIPT
![Page 1: EMERGING APPROACHES TO COMBINATION THERAPIES IN AMD & DME](https://reader036.vdocuments.site/reader036/viewer/2022062503/58ecbf6e1a28abb35d8b46e3/html5/thumbnails/1.jpg)
1. Therapeutic promise of the targets and proposed
mechanisms of action just presented?
Other promising approaches not presented?
![Page 2: EMERGING APPROACHES TO COMBINATION THERAPIES IN AMD & DME](https://reader036.vdocuments.site/reader036/viewer/2022062503/58ecbf6e1a28abb35d8b46e3/html5/thumbnails/2.jpg)
2. From a clinical perspective, where is the unmet need in DME and wet AMD? Neuroprotection, anti-fibrosis, anti-permeability,
anti-angiogenesis, other?
![Page 3: EMERGING APPROACHES TO COMBINATION THERAPIES IN AMD & DME](https://reader036.vdocuments.site/reader036/viewer/2022062503/58ecbf6e1a28abb35d8b46e3/html5/thumbnails/3.jpg)
3. As these and other phase 2/3 trials approach proof of concept, what will represent a clinically meaningful visual improvement above and beyond anti-VEGF-A therapy? A mean improvement
of 4-5 letters? Injection burden? Other?
![Page 4: EMERGING APPROACHES TO COMBINATION THERAPIES IN AMD & DME](https://reader036.vdocuments.site/reader036/viewer/2022062503/58ecbf6e1a28abb35d8b46e3/html5/thumbnails/4.jpg)
4. Assuming approval of one or more of the discussed drugs as add-on or adjunctive therapy,
how will this impact patient flow and injection practices?
What will retina practices look like in 2020?
![Page 5: EMERGING APPROACHES TO COMBINATION THERAPIES IN AMD & DME](https://reader036.vdocuments.site/reader036/viewer/2022062503/58ecbf6e1a28abb35d8b46e3/html5/thumbnails/5.jpg)